KRAS and cancer: Although our data suggested that KRAS signaling inhibitors can serve as promising combination partners for CDK9i, recent studies have proposed targeting the guanine exchange factor son of sevenless 1 (SOS1), a node that positively modulates KRAS kinase activity, as a potential therapeutic strategy for KRAS‐mutant cancers.